2-哌啶羧酸,1,1-二甲基乙基酯,(R)- | 140646-13-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-哌啶羧酸,1,1-二甲基乙基酯,(R)-
• 中文别名: (R)-2-哌啶甲酸叔丁酯
• 英文名称: tert-butyl (R)-piperidine-2-carboxylate
• 英文别名: Tert-butyl (r)-2-piperidinecarboxylate；tert-butyl (2R)-piperidine-2-carboxylate
• CAS: 140646-13-5
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: MESKMUAFJDWOAR-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-哌啶羧酸,1,1-二甲基乙基酯,(R)- 在 ammonium hydroxide 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 3.0h， 生成 (2R)-1-(2-Benzyl-3-mercaptopropanoyl)piperidine-2-carboxylic acid
  参考文献：
  名称：

  Challenges in the Development of a Thiol-Based Broad-Spectrum Inhibitor for Metallo-β-Lactamases

  摘要：

  Pathogens, expressing metallo-beta-lactamases (MBLs), become resistant against most beta-lactam antibiotics. Besides the dragging search for new antibiotics, development of MBL inhibitors would be an alternative weapon against resistant bacterial pathogens. Inhibition of resistance enzymes could restore the antibacterial activity of beta-lactams. Various approaches to MBL inhibitors are described; among others, the promising motif of a zinc coordinating thiol moiety is very popular. Nevertheless, since the first report of a thiol-based MBL inhibitor (thiomandelic acid) in 2001, no steps in development of thiol based MBL inhibitors were reported that go beyond clinical isolate testing. In this study, we report on the synthesis and biochemical characterization of thiol-based MBL inhibitors and highlight the challenges behind the development of thiol-based compounds, which exhibit good in vitro activity toward a broad spectrum of MBLs, selectivity against human off targets, and reasonable activity against clinical isolates.

  DOI：

  10.1021/acsinfecdis.7b00129
• 作为产物：
  描述：

  (R)-tert-butyl 5-(1,3-dioxolan-2-yl)-2-(diphenylmethyleneamino)pentanoate 在 三氟乙酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 反应 25.0h， 以75%的产率得到2-哌啶羧酸,1,1-二甲基乙基酯,(R)-
  参考文献：
  名称：

  通过不对称相转移催化烷基化 立体选择性合成环状氨基酸†

  摘要：

  具有以下结构的环状氨基酸的不对称合成 哌啶 沸腾岩心的结构是从容易获得开始实现的 甘氨酸 通过相转移催化的不对称烷基化反应和随后的还原胺化反应，生成丙氨酸和丙氨酸酯。

  DOI：

  10.1039/c2ob26778k

文献信息

• 삼차 아민-함유 약물 물질의 표적화된 전달
  申请人：SEAGEN INC. 씨젠 인크. (520060176231)

  公开号：KR20170053648A

  公开（公告）日：2017-05-16

  사차화된 약물 유닛이 표적화 리간드에 연결되어 있고 그것으로부터 삼차 아민-함유 약물이 표적화된 작용 부위로부터 방출되는 화합물 및 조성물이 개시된다. 예컨대 암과 같이 표적화된 비정상 세포를 특징으로 하는 질환 또는 자기면역 질환을 발명의 화합물 및 조성물을 사용하여 치료하는 방법이 또한 개시된다.

  经过修饰的药物单元与靶向配体相结合，并从其释放出来的化合物和组合物作用于靶向的活性位点。例如，使用发明的化合物和组合物治疗以异常细胞如癌症为特征的疾病或自身免疫性疾病的方法也已经开始。
• Composition for the treatment of damaged tissue
  申请人：Pfizer Inc.

  公开号：US20030199440A1

  公开（公告）日：2003-10-23

  A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

  描述了一种用于受损组织，如伤口治疗（例如愈合）的药物。该药物包括包含以下成分的组合物：（a）生长因子；和（b）抑制剂；以及可选的（c）药用载体、稀释剂或赋形剂；其中抑制剂可以抑制至少一种在受损组织，如伤口环境中上调的特定不良蛋白质（例如特定蛋白酶）的作用。
• Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation
  作者：Joseph Z. Hamilton、Thomas A. Pires、Jamie A. Mitchell、Julia H. Cochran、Kim K. Emmerton、Margo Zaval、Ivan J. Stone、Martha E. Anderson、Steven Jin、Andrew B. Waight、Robert P. Lyon、Peter D. Senter、Scott C. Jeffrey、Patrick J. Burke

  DOI：10.1002/cmdc.202000889

  日期：2021.4.8

  this work, we examine the ability of the drug‐linker and conjugation site to preserve acetate stability. Our findings show that, in contrast to a more conventional protease‐cleavable dipeptide linker, the β‐glucuronidase‐cleavable glucuronide linker protects against acetate hydrolysis and improves ADC activity in vivo. In addition, site‐specific conjugation can positively impact both acetate stability

  近年来，微管蛋白抑制剂已成为一种引人注目的药物，可通过抗体递送至肿瘤细胞。此类药物能够发挥旁观者活性，同时保留针对多重耐药细胞系的效力，这使得它们有别于其他微管破坏剂。Tubulysin M 是一种合成类似物，已被证明作为抗体药物偶联物 (ADC) 有效负载具有活性和良好的耐受性，但容易在 C11 位点发生醋酸盐水解，从而导致效力减弱。在这项工作中，我们检查了药物接头和缀合位点保持乙酸盐稳定性的能力。我们的研究结果表明，与更传统的蛋白酶可切割的二肽连接体相比，β-葡萄糖醛酸酶可切割的葡萄糖醛酸连接体可防止乙酸盐水解并提高体内ADC 活性。此外，位点特异性缀合可以对乙酸盐稳定性和体内活性产生积极影响。总之，这些发现为微管蛋白抑制剂高度优化的递送策略提供了基础。
• Process for synthesis of FK-506 and tricarbonyl intermediates
  申请人：Merck & Co., Inc.

  公开号：EP0378318A1

  公开（公告）日：1990-07-18

  A process is described for the total synthesis of the macrolide immunosuppressant, FK-506, and important tricarbonyl process intermediates thereof. The tricarbonyl intermediates can be produced by the mild oxidation of 2,3-dihydroxy carboxylate compounds containing olefin moieties.

  本文描述了一种合成大环内酯免疫抑制剂FK-506及其重要的三羰基过程中间体的全合成过程。这些三羰基中间体可以通过含有烯烃基团的2,3-二羟基羧酸酯化合物的温和氧化制备。
• Isoquinolines
  申请人：——

  公开号：US06093731A1

  公开（公告）日：2000-07-25

  Isoquinolinylguanidine compounds of formula (I): ##STR1## wherein the substituents are as defined herein, and salts thereof, are disclosed as urokinase inhibitors.

  本文披露了式（I）的异喹啉基脲化合物：##STR1## 其中取代基的定义如本文所述，以及其盐，作为尿激酶抑制剂。